SAB Biotherapeutics Inc
SABS1.790USD
+0.070+4.07%
Cierre 05/09, 16:00（ET）Cotizaciones retrasadas 15 min
16.63MCap. mercado
PérdidaP/E TTM
Más Datos de SAB Biotherapeutics Inc Compañía
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
Información de la empresa
Código de la empresaSABS
Nombre de la empresaSAB Biotherapeutics Inc
Fecha de salida a bolsaJan 12, 2021
Fundada en2020
Director ejecutivoMr. Samuel J. Reich
Número de empleados63
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 12
Dirección777 W 41St St
CiudadMIAMI BEACH
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal33140
Teléfono13058452813
Sitio Webhttps://www.sab.bio/
Código de la empresaSABS
Fecha de salida a bolsaJan 12, 2021
Fundada en2020
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Christine E. Hamilton
Ms. Christine E. Hamilton
Independent Director
Independent Director
501.81K
+0.50%
Dr. Alexandra Kropotova, M.D.
Dr. Alexandra Kropotova, M.D.
Chief Medical Officer
Chief Medical Officer
26.52K
+68.72%
Mr. Jeffrey G. Spragens
Mr. Jeffrey G. Spragens
Independent Director
Independent Director
--
--
Mr. David Link
Mr. David Link
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Ms. Lucy To
Ms. Lucy To
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Andrew D. Moin
Mr. Andrew D. Moin
Independent Director
Independent Director
--
--
Mr. Samuel J. Reich
Mr. Samuel J. Reich
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Erick J. Lucera
Mr. Erick J. Lucera
Independent Director
Independent Director
--
--
Dr. William J. Polvino, M.D.
Dr. William J. Polvino, M.D.
Independent Director
Independent Director
--
--
Ms. Katie Katherine Ellias
Ms. Katie Katherine Ellias
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Christine E. Hamilton
Ms. Christine E. Hamilton
Independent Director
Independent Director
501.81K
+0.50%
Dr. Alexandra Kropotova, M.D.
Dr. Alexandra Kropotova, M.D.
Chief Medical Officer
Chief Medical Officer
26.52K
+68.72%
Mr. Jeffrey G. Spragens
Mr. Jeffrey G. Spragens
Independent Director
Independent Director
--
--
Mr. David Link
Mr. David Link
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Ms. Lucy To
Ms. Lucy To
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Andrew D. Moin
Mr. Andrew D. Moin
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Accionista
Hora de actualización: vie., 9 de may
Hora de actualización: vie., 9 de may
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
BVF Partners L.P.
9.88%
Sullivan (Eddie Joe)
5.63%
Hamilton (Christine E)
5.40%
Marshall Wace LLP
4.94%
Sessa Capital
4.93%
Other
69.21%
Estadísticas de accionistas
Accionista
Proporción
BVF Partners L.P.
9.88%
Sullivan (Eddie Joe)
5.63%
Hamilton (Christine E)
5.40%
Marshall Wace LLP
4.94%
Sessa Capital
4.93%
Other
69.21%
Tipo
Accionista
Proporción
Hedge Fund
15.47%
Individual Investor
15.38%
Investment Advisor/Hedge Fund
11.97%
Investment Advisor
0.84%
Corporation
0.59%
Family Office
0.55%
Bank and Trust
0.20%
Venture Capital
0.18%
Other
54.83%
Participación institucional
Hora de actualización: mar., 4 de mar
Hora de actualización: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
81
4.43M
47.74%
-1.20M
2024Q4
84
4.36M
47.19%
-1.19M
2024Q3
92
4.88M
52.85%
-650.39K
2024Q2
94
4.85M
52.54%
-723.93K
2024Q1
99
5.12M
55.54%
-327.29K
2023Q4
101
5.29M
57.38%
+3.28M
2023Q3
126
1.82M
35.87%
-989.33K
2023Q2
130
1.88M
37.39%
-929.45K
2023Q1
128
1.84M
36.63%
-1.01M
2022Q4
121
1.84M
42.70%
-908.11K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BVF Partners L.P.
917.83K
9.88%
--
--
Dec 31, 2024
Sullivan (Eddie Joe)
523.23K
5.63%
--
--
May 13, 2024
Hamilton (Christine E)
499.31K
5.38%
--
--
May 13, 2024
Marshall Wace LLP
459.17K
4.94%
--
--
Dec 31, 2024
Sessa Capital
458.46K
4.94%
--
--
Dec 31, 2024
Hamilton (Edward D.)
308.32K
3.32%
--
--
May 13, 2024
The Vanguard Group, Inc.
277.38K
2.99%
+1.04K
+0.38%
Dec 31, 2024
Homrich Berg
237.40K
2.56%
+128.80K
+118.60%
Dec 31, 2024
Geode Capital Management, L.L.C.
80.23K
0.86%
+12.69K
+18.79%
Dec 31, 2024
Big Cypress Holdings, L.L.C.
54.77K
0.59%
--
--
May 13, 2024
Ver más
ETFs relacionados
Hora de actualización: mar., 6 de may
Hora de actualización: mar., 6 de may
Nombre
Proporción
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Jan 02, 2024
Merger
10<1
Jan 02, 2024
Merger
10<1
Jan 02, 2024
Merger
10<1
Jan 02, 2024
Merger
10<1
Fecha
Tipo
Relación
Jan 02, 2024
Merger
10<1
Jan 02, 2024
Merger
10<1
Jan 02, 2024
Merger
10<1
Jan 02, 2024
Merger
10<1